8-K: HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma has finalized the design for its pivotal Phase 2/3 trial of HB-200 in combination with pembrolizumab for the treatment of HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma.

Summary

• HOOKIPA Pharma has announced the final design for its Phase 2/3 clinical trial of HB-200 in combination with pembrolizumab.
• The trial will focus on patients with HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma (OPSCC) who have a PD-L1 CPS of 20 or more.
• The trial design is based on feedback from the FDA following a Type C meeting.
• The study will enroll approximately 250 patients in a seamless Phase 2/3 design.
• Patients will be randomized 1:1 to receive either HB-200 plus pembrolizumab or placebo plus pembrolizumab.
• The primary endpoint for Phase 2 is objective response rate (ORR), and for Phase 3 it is overall survival.
• The company may seek accelerated approval based on Phase 2 data, which is expected in 2026.
• An oral presentation of data from approximately 40 patients treated with HB-200 and pembrolizumab will be given at the ASCO 2024 Annual Meeting in June.

Sentiment

Score: 8

Explanation: The document is very positive, highlighting a significant step forward in clinical development, alignment with regulatory bodies, and promising early data. The potential for accelerated approval and the company's confidence in their approach contribute to a strong positive sentiment.

Positives

• The Phase 2/3 trial design has been aligned with the FDA, which may streamline the regulatory process.
• HB-200 has received both Fast Track and PRIME designations, which can expedite development and review.
• The company has presented promising early data with a 42% ORR and 74% disease control rate in a Phase 1/2 trial.
• The company is planning to present updated data at the ASCO 2024 Annual Meeting.
• The trial design includes a potential for accelerated approval based on Phase 2 data.

Negatives

• The trial is still in the early stages, with the first patient enrollment expected in the fourth quarter of 2024.
• The primary analysis of Phase 2 data is not expected until 2026, which means a potential delay in market approval.
• The trial involves a placebo control arm, which may not be ideal for patients with advanced cancer.

Risks

• The success of the trial is not guaranteed, and results may not be as positive as previous data.
• Regulatory approval is not certain, and the FDA may require additional data or studies.
• The company may face challenges in enrolling the required number of patients for the trial.
• There are risks associated with manufacturing the drug product and ensuring its quality.
• The company's intellectual property may be challenged, which could impact its ability to commercialize the product.

Future Outlook

The company anticipates the first patient will be enrolled in the fourth quarter of 2024, with a primary analysis of Phase 2 data expected in 2026, potentially leading to an accelerated approval filing.

Management Comments

• Joern Aldag, CEO of HOOKIPA, stated that the company is taking a big step forward in translating their science into a product that will impact patients.
• The CEO believes their data is best-in-class and puts them in the lead position for OPSCC in the first-line setting.
• The CEO also mentioned that the trial design and alignment with regulators can help them reach potential registration more quickly.

Industry Context

This announcement is significant in the context of the immuno-oncology field, as it represents a potential new treatment option for patients with HPV16+ recurrent or metastatic OPSCC. The combination of HB-200 with pembrolizumab is aimed at improving outcomes for patients who have limited treatment options.

Comparison to Industry Standards

• The reported 42% ORR for HB-200 in combination with pembrolizumab is a significant improvement over the 19% ORR for pembrolizumab alone, as seen in the KEYNOTE-048 study.
• The trial design is similar to other pivotal trials in the field, using a randomized, placebo-controlled approach.
• The use of a seamless Phase 2/3 design is a common strategy to accelerate drug development.
• The company's focus on HPV16+ OPSCC aligns with the growing understanding of the role of HPV in head and neck cancers.

Stakeholder Impact

• Shareholders may see a positive impact due to the advancement of the clinical trial and potential for accelerated approval.
• Patients with HPV16+ OPSCC may benefit from a new treatment option.
• Employees of HOOKIPA may be motivated by the progress of the company's lead candidate.
• The company's collaboration with Gilead may also be positively impacted.

Next Steps

• Enrollment of the first patient in the Phase 2/3 trial is expected in the fourth quarter of 2024.
• The company will present data from approximately 40 patients at the ASCO 2024 Annual Meeting in June.
• The primary analysis of Phase 2 data is expected in 2026.
• The company may seek accelerated approval based on Phase 2 data.

Key Dates

Keywords

HB-200, Pembrolizumab, HPV16+, OPSCC, Immunotherapy, Clinical Trial, Phase 2/3, FDA, ASCO, Oncology